Comparison of new reversal agent, Sugammadex and standard reversal agent Neostigmine-Glycopyrrolate on Stomach Volume After uterine removal surgery: A Pilot Randomised Study

INTERVENTION: Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Sugammade X2 mg/kg IV: Patients in group‐ S will receive sugammade X2 mg/kg intravenous once and glycopyrrolate 0.2 mg intravenous once. Total volume will remain 10 ml. Control Intervention1: Group‐N patients will receive neostigmine 0.07 mg/kg IV: Group‐N patients will receive neostigmine 0.07 mg/kg intravenous once and glycopyrrolate once (0.2 mg intravenous per 1 mg of neostigmine). Total volume will remain 10 ml. CONDITION: Health Condition 1: N72‐ Inflammatory disease of cervi Xuteri PRIMARY OUTCOME: Difference in gastric antral volume from baseline to 30 minutes following neuromuscular blockade reversal agent administration ; Timepoint: Baseline gastric antral volume and gastric volume after 30 minutes following neuromuscular blockade reversal agent administration ; SECONDARY OUTCOME: To compare the followings parameters between the two groups. ; Quantitative Gastric antral volume assessment at 3 hours after neuromuscular blockade reversal agent administration, ; Time to first flatus or bowel movement, ; Postoperative nausea and vomiting, ; Placement of NG tube in total number of patients ; Length of Hospital stay in days, ; Post Operative Ileus incidence at postoperative day 4.Timepoint: 3 hours and day 4 INCLUSION CRITERIA: Patients with ASA PS I‐II, aged 18‐65 undergoing elective total abdominal hysterectomy under general anesthesia will be included.